For localized information and support, would you like to switch to your country-specific website for {0}?
Value in clinical practice: HbA1c Point of Care Testing (POCT) for better diabetes care
playicon
videoCtrl
/
fullScreen
Update Required
To play the media you will need to either update your browser to a recent version or update your
Flash plugin.
The ever-increasing global burden of diabetes—and the fact that up to 50% of patients remain undiagnosed1—present a significant problem. One that creates a huge demand for robust and accurate diagnostic methods to aid in timely diagnosis, earlier treatment interventions and consequently better patient outcomes.
Dr. Erna Lenters-Westra, renowned glycated hemoglobin expert, gives her insights into HbA1c POCT. She reveals results of her research and shares valuable knowledge about HbA1c testing and which factors are important for ensuring a high-quality standard.
One main barrier to HbA1c POCT implementation was the global variations in platforms and instruments, as well as guidelines, methods, and standards. But over time, IFCC and NGSP worked to drive standardization of HbA1c reporting and traceability, enabling HbA1c to become a valuable and standardization tool to clinicians at the point of care.
Dr. Erna Lenters-Westra stresses the importance of external quality assessments (EQA) to ensure high quality testing. Tune in to discover an example of a quality framework—used with success in Norway—that Dr. Lenters-Westra believes to be essential to establishing best practice POCT. Hear why EQA data is considered the "holy grail" for assessing instruments and find out why analytical performance is not the only factor to consider when looking to bring value to patient care.
We hope you enjoy this insightful and informative webinar.
References:
- IDF Diabetes Atlas. (2019). Ninth edition.
The views and opinions expressed in this webinar are those of the speakers and do not necessarily reflect the views or positions of Roche or any other sponsors.